| Dr Timothy Donald Macon, DO,FCCP | |
|
780 N Gavord Rd, Sterling, MI 48659-9703 | |
| (989) 654-2168 | |
| (989) 654-2825 |
| Full Name | Dr Timothy Donald Macon |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 35 Years |
| Location | 780 N Gavord Rd, Sterling, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679561443 | NPI | - | NPPES |
| 115651012 | Other | MI | BLUE CROSS BLUE SHIELD |
| 302002 | Other | MA | CENTRAL HEALTH PLAN OF MI |
| 4509887 | Other | MI | AETNA |
| 110216075 | Other | MI | RAIL ROAD MEDICARE |
| 383563124 | Other | MI | PPOM |
| 383563124 | Other | MI | UNITED HEALTH PLAN |
| 1007603 | Other | MI | MCLAREN HEALTH PLAN |
| 383563124101 | Other | MI | COMMUNITY CHOICE OF MICH |
| 1000781 | Other | MA | MCLAREN HEALTH ADVANTAGE |
| 122278 | Other | MI | PREFERRED CHOICE |
| 383563124 | Other | MI | UNITED HEALTH CARE |
| 115651012 | Other | MI | BLUE CARE NETWORK |
| 4261168 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | TM009037 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beaumont Hospital, Troy | Troy, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Beaumont Medical Group- Specialty Services | 7214299866 | 787 |
News Archive
Lawrence Livermore National Laboratory scientists have paired 3D-printed, living human brain vasculature with advanced computational flow simulations to better understand tumor cell attachment to blood vessels, the first step in secondary tumor formation during cancer metastasis.
The drug combination of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil (elvitegravir fixed combination, trade name: Stribild) has been approved in Germany since May 2013 for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1).
Leber congenital amaurosis (LCA) is a congenital retinal dystrophy present in approximately 1 of 80,000 births. It is estimated that about 3,000 people in the United States are living with LCA and will likely become blind in their lifetimes. Recently, there has been progress in gene therapy for this condition.
Years before inflammatory bowel disease (IBD) is diagnosed and symptoms exist, biomarkers are already circulating that can help predict risk not only of disease development but also of complications, according to research published online last week, which will also appear in the June 15th print issue of Alimentary Pharmacology & Therapeutics.
› Verified 1 days ago
| Entity Name | William Beaumont Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083833875 PECOS PAC ID: 9335051093 Enrollment ID: O20031104000279 |
News Archive
Lawrence Livermore National Laboratory scientists have paired 3D-printed, living human brain vasculature with advanced computational flow simulations to better understand tumor cell attachment to blood vessels, the first step in secondary tumor formation during cancer metastasis.
The drug combination of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil (elvitegravir fixed combination, trade name: Stribild) has been approved in Germany since May 2013 for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1).
Leber congenital amaurosis (LCA) is a congenital retinal dystrophy present in approximately 1 of 80,000 births. It is estimated that about 3,000 people in the United States are living with LCA and will likely become blind in their lifetimes. Recently, there has been progress in gene therapy for this condition.
Years before inflammatory bowel disease (IBD) is diagnosed and symptoms exist, biomarkers are already circulating that can help predict risk not only of disease development but also of complications, according to research published online last week, which will also appear in the June 15th print issue of Alimentary Pharmacology & Therapeutics.
› Verified 1 days ago
| Entity Name | Pulmonary & Critical Care Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598700932 PECOS PAC ID: 0547250607 Enrollment ID: O20040512001399 |
News Archive
Lawrence Livermore National Laboratory scientists have paired 3D-printed, living human brain vasculature with advanced computational flow simulations to better understand tumor cell attachment to blood vessels, the first step in secondary tumor formation during cancer metastasis.
The drug combination of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil (elvitegravir fixed combination, trade name: Stribild) has been approved in Germany since May 2013 for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1).
Leber congenital amaurosis (LCA) is a congenital retinal dystrophy present in approximately 1 of 80,000 births. It is estimated that about 3,000 people in the United States are living with LCA and will likely become blind in their lifetimes. Recently, there has been progress in gene therapy for this condition.
Years before inflammatory bowel disease (IBD) is diagnosed and symptoms exist, biomarkers are already circulating that can help predict risk not only of disease development but also of complications, according to research published online last week, which will also appear in the June 15th print issue of Alimentary Pharmacology & Therapeutics.
› Verified 1 days ago
| Entity Name | Beaumont Medical Group- Specialty Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578072906 PECOS PAC ID: 7214299866 Enrollment ID: O20180320002549 |
News Archive
Lawrence Livermore National Laboratory scientists have paired 3D-printed, living human brain vasculature with advanced computational flow simulations to better understand tumor cell attachment to blood vessels, the first step in secondary tumor formation during cancer metastasis.
The drug combination of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil (elvitegravir fixed combination, trade name: Stribild) has been approved in Germany since May 2013 for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1).
Leber congenital amaurosis (LCA) is a congenital retinal dystrophy present in approximately 1 of 80,000 births. It is estimated that about 3,000 people in the United States are living with LCA and will likely become blind in their lifetimes. Recently, there has been progress in gene therapy for this condition.
Years before inflammatory bowel disease (IBD) is diagnosed and symptoms exist, biomarkers are already circulating that can help predict risk not only of disease development but also of complications, according to research published online last week, which will also appear in the June 15th print issue of Alimentary Pharmacology & Therapeutics.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Timothy Donald Macon, DO,FCCP 780 N Gavord Rd, Sterling, MI 48659-9703 Ph: (989) 654-2168 | Dr Timothy Donald Macon, DO,FCCP 780 N Gavord Rd, Sterling, MI 48659-9703 Ph: (989) 654-2168 |
News Archive
Lawrence Livermore National Laboratory scientists have paired 3D-printed, living human brain vasculature with advanced computational flow simulations to better understand tumor cell attachment to blood vessels, the first step in secondary tumor formation during cancer metastasis.
The drug combination of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil (elvitegravir fixed combination, trade name: Stribild) has been approved in Germany since May 2013 for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1).
Leber congenital amaurosis (LCA) is a congenital retinal dystrophy present in approximately 1 of 80,000 births. It is estimated that about 3,000 people in the United States are living with LCA and will likely become blind in their lifetimes. Recently, there has been progress in gene therapy for this condition.
Years before inflammatory bowel disease (IBD) is diagnosed and symptoms exist, biomarkers are already circulating that can help predict risk not only of disease development but also of complications, according to research published online last week, which will also appear in the June 15th print issue of Alimentary Pharmacology & Therapeutics.
› Verified 1 days ago
Dr. Bassel Ahmad, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 725 E State St, Sterling, MI 48659 Phone: 989-654-2491 | |
Linda Caren Runyon, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 725 E State St, Sterling Area Health Center, Sterling, MI 48659 Phone: 989-654-2491 Fax: 989-654-2190 | |
Brian J Gedeon, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 725 E State St, Sterling, MI 48659 Phone: 989-654-2491 Fax: 989-654-2190 |